Air Ambulance-Happy New Year 2019-Year of Change

Home / Blog / Air Ambulance-Happy New Year 2019-Year of Change
Air Ambulance-Happy New Year 2019-Year of Change

Air Ambulance-Happy New Year 2019-Year of Change for Air Ambulance Worldwide

Air Ambulance - New Year 2019

Medicine is always changing and 2018 was no exception. 

Year 2018 was a year of change with lots of changes happening in thoughts and plans about Medevac. The things we thought is the right way to do was no longer right and change has happened whereby things were done in an economical way and insurance companies have accepted that mode.

Understanding these “game changers” is critical to staying at the cutting edge of  the business of aviation. 
Companies have started accepted the fact that the critical patient on ventilator can be transported on Airline Stretcher too!

And Train Ambulance - a new concept was accepted by most insurance companies.

Director of HI Flying Air Ambulance International

There also been changes in Hospital and Medical practice scenario.

Here are a few such pieces from 2018.

For a large fraction of our professional lives, we have been telling patients who suffered from a prior major cardiovascular event, such as myocardial infarction or stroke, that daily oral intake of about 82 mg of aspirin a day could help protect against  future events. Since the intervention was perceived to have few side effects, many of us advised previously healthy older adults to take a daily low-dose aspirin to protect against cardiovascular disease. This daily regimen was inexpensive, low-risk  and appeared to provide a benefit. But a trio of studies published last September found that a daily aspirin doesn’t do much good, and may even cause harm.

Peanut allergy is another diagnosis where we were compelled to shift our mindset. For decades, the advice, once the allergy was confirmed, was to stay away from peanuts for the rest of your life. It was possible to desensitize people, but the procedures are difficult and entail substantial risk. However, the PALISADE trial, published in November, described a new peanut oral immunotherapy that, when introduced to patients with peanut allergy, could desensitize children and adolescents who were highly allergic to peanuts. Although there were side effects, the use of a highly refined and standardized peanut allergen, provided a reasonable margin of safety.
Many such changes are on the horizon as we look forward to year 2019 for more meaningful improvements in medical practice and patient care. 

From the Director's Desk - HI Flying - Air Ambulance International

Share & Comment:

Contact Us

Call Us
+1 412 567 2211
whatsapp icon